Krystal Biotech downgraded: VYJUVEK's success becomes a growth problem
FROM THE WIRE · SEEKINGALPHA.COM
Krystal Biotech is downgraded from Buy to Hold as U.S. VYJUVEK sales plateau and growth shifts ex-U.S. Read more on KRYS stock here.
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bearishSlowing U.S. VYJUVEK sales and shift of growth to ex-U.S. markets signal product maturation phase.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Krystal Biotech downgraded from Buy to Hold by analysts.
- 02U.S. VYJUVEK sales are plateauing in growth trajectory.
- 03Future growth increasingly dependent on international markets.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets